From a molecular retail viewpoint, Relafen 750, containing naproxen, represents a fascinating case study in medication action. Its chief mechanism involves blocking cyclooxygenase (COX) enzymes, specifically COX-2, which results in reduced synthesis of prostaglandins . This selective inhibition diminishes tenderness and ache associated with conditi